LINC02604: A Long Intergenic Non-Protein Coding RNA (G644794)

Target Name: LINC02604

NCBI ID: G644794

LINC02604

Other Name(s): long intergenic non-protein coding RNA 2604 | lncHERG | Long intergenic non-protein coding RNA 2604

LINC02604: A Long Intergenic Non-Protein Coding RNA

LINC02604 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various studies as having various functionalities, including the regulation of gene expression, DNA replication, and chromatin remodeling. LncRNAs, as their name suggests, are non-protein coding RNAs that are longer than 200 nucleotides and are not known to function as traditional proteins. However, recent studies have shown that lncRNAs play a significant role in various cellular processes, including development, growth, and metabolism.

Disease association

LINC02604 has been associated with several diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that lncRNA expression is often altered in various diseases, including cancer, and that these changes can be used as biomarkers for disease diagnosis and prognosis.

Drug targeting

Due to its various functionalities, LINC02604 has also been identified as a potential drug target. The expression of LINC02604 has been shown to be regulated by various factors, including gene expression, DNA replication, and chromatin remodeling. Therefore, targeting LINC02604 using small molecules or other therapeutic approaches may be a promising strategy for the treatment of various diseases.

Biomarker potential

LINC02604 has also been shown to be involved in the regulation of gene expression and has been used as a potential biomarker for various diseases. For example, studies have shown that LINC02604 is involved in the regulation of cell proliferation and has been associated with the development of various cancers. Therefore, measuring the expression of LINC02604 may be a promising approach for the diagnosis and prognosis of cancer.

Expression regulation

LINC02604 has been shown to be regulated by various factors, including gene expression, DNA replication, and chromatin remodeling. These regulatory mechanisms have been studied extensively and have led to a better understanding of the function of LINC02604.

Gene expression regulation

LINC02604 has been shown to be regulated by various genes, including APC1, APC2, and DICER2. These genes have been shown to play a role in the regulation of LINC02604 expression and in the regulation of cellular processes, including cell proliferation and DNA replication.

DNA replication regulation

LINC02604 has also been shown to be regulated by the factor DNMT2. DNMT2 is a DNA methyltransferase that has been shown to play a role in the regulation of various RNAs, including LINC02604. Therefore, the regulation of LINC02604 by DNMT2 may be an important aspect to consider in the regulation of LINC02604 expression.

Chromatin remodeling

LINC02604 has also been shown to be involved in the regulation of chromatin remodeling and has been associated with various diseases, including cancer. Therefore, the regulation of LINC02604 by chromatin remodeling factors may be an important aspect to consider in the regulation of LINC02604 expression.

Conclusion

LINC02604 is a long intergenic non-protein coding RNA that has been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its functionalities include the regulation of gene expression, DNA replication, and chromatin remodeling. Therefore, LINC02604 has the potential to be a drug target or biomarker for various diseases. Further studies are needed to fully understand the regulation of LINC02604 and its potential clinical applications.

Protein Name: Long Intergenic Non-protein Coding RNA 2604

The "LINC02604 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02604 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets